Report on the status of women occupying leadership roles in oncology
Eva Hofstädter-Thalmann, Solange Peters(University Hospital of Lausanne), Tamara Allen, John B.A.G. Haanen(Leiden University Medical Center), Panagiota Zygoura(Frontier Science Foundation-Hellas), Zoi Tsourti(Frontier Science Foundation-Hellas), Dirk Arnold(Asklepios Klinik Altona), Elena Garralda(Memorial Sloan Kettering Cancer Center), Susana Banerjee(Royal Marsden NHS Foundation Trust), Urania Dafni(Frontier Science Foundation-Hellas), Cristiana Sessa(Institute of Oncology Research), Marina Chiara Garassino(University of Chicago), Caroline Robert(Institut Gustave Roussy), Giuseppe Curigliano(European Institute of Oncology)
Cited by 49
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
|Annals of Oncology|2018|2.9k